5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 239/70 (2006.01) A61K 31/517 (2006.01) A61P 35/00 (2006.01) C07D 401/04 (2006.01) C07D 401/10 (2006.01) C07D 409/04 (2006.01) C07D 417/04 (2006.01) C07D 487/04 (2006.01)

Patent

CA 2711782

Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

La présente invention concerne des composés représentés par la formule (I) qui se révèlent utiles pour inhiber les protéines kinases Akt. La présente invention concerne également des méthodes d'utilisation des composés représentés par la formule (I), ainsi que des stéréoisomères et des sels pharmaceutiquement acceptables de ces composés, pour le diagnostic, la prévention ou le traitement in vitro, in situ, et in vivo de tels troubles, ou de pathologies associées, dans des cellules mammaliennes. Formule (I).

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1599138

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.